Drugs that contain Dacomitinib

1. List of Vizimpro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(2 years from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 27, 2025
New Chemical Entity Exclusivity (NCE) Sep 27, 2023

NCE-1 date: September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic